Novavax COVID-19 Vaccine Demonstrates 89.3% Efficacy in UK Phase 3 Trial

Novavax, Inc. today announced that NVX-CoV2373, its protein-based COVID-19 vaccine candidate, met the primary endpoint, with a vaccine efficacy of 89.3%, in its Phase 3 clinical trial conducted in the United Kingdom (UK).

Photo by CDC on Unsplash

https://web.archive.org/web/20210128212457/https://ir.novavax.com/news-releases/news-release-details/novavax-covid-19-vaccine-demonstrates-893-efficacy-uk-phase-3

India starts world’s largest COVID-19 vaccination drive

India started inoculating health workers Saturday in what is likely the world’s largest COVID-19 vaccination campaign, joining the ranks of wealthier nations where the effort is already well underway.

https://apnews.com/article/health-india-immunizations-coronavirus-pandemic-ab830864393480ea6dcc67b0571fc29c

India approves Oxford/AstraZeneca vaccine for emergency use in major breakthrough for Covid fightback

India has given a green light for emergency use of the Oxford-AstraZeneca vaccine, making it the first jab to be granted approval by regulators in the Covid-19 pandemic’s second worst-hit country.

https://www.independent.co.uk/news/world/asia/india-covid-vaccine-oxford-astrazeneca-b1781201.html